Breaking Finance News

Endocyte, Inc. (NASDAQ:ECYT) target price raised to $1.75, reported today by Zacks Investment Research

Endocyte, Inc. (NASDAQ:ECYT) had its stock price target increased to $1.75 by Zacks Investment Research in an issued report issued Thursday June 08, 2017. The upped price target indicates a possible upside of 0.11% based on the company's previous stock price.

Just yesterday Endocyte, Inc. (NASDAQ:ECYT) traded -0.83% lower at $1.57. Endocyte, Inc.’s 50-day moving average is $2.27 and its 200-day moving average is $2.00. The last stock price is down 140.05% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.03% over the same time period. 1,052,826 shares of ECYT traded hands, down from an average trading volume of 2,810,750

Recent Performance Chart

Endocyte, Inc. (NASDAQ:ECYT)

Endocyte, Inc. has 52 week low of $1.17 and a 52 week high of $6.55 and has a market capitalization of $0.

Brief Synopsis On Endocyte, Inc. (NASDAQ:ECYT)

Endocyte Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company's pipeline includes Folate-Tubulysin (EC1456), the Company's second generation SMDC, also targets the folate receptor; PSMA Tubulysin (EC1169), the Company's non-folate SMDC, which is a tubulysin therapeutic targeting PSMA; Vintafolide (Folate DAVLBH), SMDC, vintafolide, targets the folate receptor with the anti-cancer drug payload DAVLBH; Folate-DNA alkylator (EC1788), which is a folate receptor-targeted SMDC with a potent DNA alkylator drug; Folate-Aminopterin (EC1669) is a folate receptor-targeted SMDC for the treatment in inflammatory diseases, and Folate-mTor inhibitor (EC0371), which is a folate receptor-targeted SMDC for the treatment of polycystic kidney disease(PKD).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.